Amphastar Pharmaceuticals, Inc. 8-K

What Happened
Amphastar Pharmaceuticals filed an 8‑K (filed March 6, 2026; effective March 3, 2026) announcing it entered into one‑year employment agreements with Jacob Liawatidewi (Executive VP, Corporate Administration Center; Secretary; director) and Rong Zhou (Senior Executive VP, Production Center). The agreements automatically renew for successive one‑year terms unless either party gives at least 90 days’ notice of non‑renewal and are terminable by the company or the executives at any time (with or without cause or good reason).

Key Details

• Effective date: March 3, 2026; filing date: March 6, 2026.
• Salaries and bonus targets: Liawatidewi — $525,800 annual base salary; target annual cash bonus = 55% of base. Zhou — $590,000 annual base salary; target annual cash bonus = 53% of base.
• Equity and benefits: Both are eligible for equity incentive awards (as determined by the board/compensation committee) and participation in company benefit plans.
• Severance on qualifying termination (company termination without cause, non‑renewal, or resignation for good reason), subject to execution of a release:
  • Lump‑sum payment equal to 2x the sum of (a) the highest annual base salary in the prior 12 months plus (b) the average annual bonus earned for the most recent two fiscal years.
  • Continued payment of group health/dental/vision premiums for up to 12 months.
  • 100% accelerated vesting of any then‑unvested equity awards.
• Change‑in‑control provisions: If a qualifying termination occurs during the period from a change in control to one year after, the executive receives an additional lump‑sum payment equal to 2x the same salary+bonus sum and an extra 12‑month extension of health premium continuation; also, a change in control alone accelerates 100% of any then‑unvested awards.
• Tax protection: If payments would be subject to IRC Section 280G excise tax, the executive will receive either the full payments or a reduced amount that avoids the excise tax—whichever yields the greater after‑tax amount.

Why It Matters
These agreements lock in compensation levels, severance protections and full vesting of equity for two senior executives, which can affect Amphastar’s cash obligations and equity dilution in certain termination or change‑in‑control scenarios. Investors should note the potential severance cash outlays (structured as multiples of salary and bonus) and the accelerated equity vesting provisions that could accelerate share issuance if a qualifying termination or change in control occurs. The full form of the employment agreement is filed as an exhibit to the 8‑K.